1   **State Medicaid Expansion Policies were Associated with Reduced Rates of**

2   **Congenital Syphilis, 2008-2022**

3   Authors: Austin M Williams, PhD[1]

4   1.   Independent researcher

Abstract

Objective:

To assess the relationship between adoption of Medicaid expansion policies and rates of congenital

syphilis (CS) in the United States.

Study Setting and Design:

Cases of CS have increased nearly 10-fold in the past decade. State (and D.C.) adoptions of Medicaid

expansion, State Plan Amendment (SPA) optional family planning eligibility groups, and Medicaid section

1115 waiver demonstration projects have increased eligibility for family planning services. The primary

outcome was the state level annual reported rate of CS per 100,000 live births. We assessed two binary

policy "treatments" of interest: 1) whether a state had adopted Medicaid expansion and 2) whether a

state had adopted either Medicaid expansion, a family planning waiver, or a family planning SPA. We

estimated dynamic and overall treatment effects using a novel difference-in-differences estimator that

accounted for variation in treatment timing. Sensitivity analyses controlled for state-level characteristics

including education, poverty, unemployment, race, ethnicity, migration, and population size change.

Data Sources and Analytic Sample:

Data were collected from CDC surveillance reports and 1-year American Community Survey files from

2008-2022.

Principal Findings:

Pre-treatment trends in CS outcomes were similar between states that implemented the Medicaid

policies and those that did not. Medicaid expansion alone was associated with a significant reduction of

6.37 (95% CI: 1.94, 10.79) cases per 100,000 live births over the first three years of the policy. Adopting

either Medicaid expansion, a family planning SPA, or a family planning waiver was related to a non-

significant reduction of 5.06 (95% CI: -3.21, 13.33) cases per 100,000 live births. Significant reductions in

CS were also found within the first year of policy adoption.

Conclusions:

This analysis found Medicaid expansion policies were associated with reductions in CS rates. Increasing

access to family planning services through Medicaid programs might reduce CS even shortly after policy

adoption.

Introduction

Addressing the rise in rates of congenital syphilis (CS) is an urgent public health priority.[1] CS occurs when

syphilis is vertically transmitted to a fetus during pregnancy and is prevented through diagnosis and

treatment of syphilis before or early during pregnancy. Untreated syphilis can have severe health

consequences, including neurologic changes and permanent vision and hearing loss for infants in

addition to impacting pregnancy outcomes.[2] Reported cases of CS in the United States have increased an

alarming 10-fold over the past decade to 3,755 cases in 2022.[1,3] CS is associated with spontaneous

abortion, stillbirth, infant death, pre-term delivery, low birth weight, and long-term health impacts for

surviving infants.[1,4] Further, hospitalizations attributable to CS have high direct medical costs.[5,6]

A variety of factors may be contributing to the syphilis and CS epidemics, and studying their social,

behavioral, and clinical determinants might yield critical information for controlling the rise of syphilis

and CS.[1,2] First, rates of CS are closely related to rates of primary and secondary (P&S) syphilis in women

of reproductive age (15-44 years), so factors contributing to the rise in P&S syphilis in this population are

relevant.[3] There is evidence of increases in sexual behaviors that are associated with STIs: condom use

has fallen among some groups in recent years,[7,8] and there may be changes in safe-sex behaviors in

response to falling HIV mortality. [9] Changes in technology may be altering the composition of sexual

networks,[10] which are a critical component of sexually transmitted infection (STI) transmission. Trends in

opioid use, methamphetamine use, and transactional sex may also be contributing to the rise in syphilis

in the U.S.[11,12] Further, healthcare disruptions during the COVID-19 pandemic likely led to reductions in

STI services.[13]

Since 2010, substantial changes to the U.S. healthcare landscape, including family planning services (e.g.,

contraception, STI services, and preconception services), also have possible implications for syphilis and

CS. Starting in 2014, as part of the Affordable Care Act (ACA), many states and the District of Columbia

(D.C.) expanded eligibility for full-benefit Medicaid, i.e., comprehensive insurance that covered all

mandatory Medicaid benefits.[14] Medicaid, the primary funding source for family planning services for

people with low incomes, has established minimum federal standards for family planning services and

supplies, with states able to set eligibility levels and determine the amount, duration, and scope of

covered benefits within broad federal parameters.[15,16] The ACA required many group and individual

health plans (i.e., private insurance) and Medicaid plans to cover preventive services without cost

sharing, including FDA approved contraceptives, STI and HIV screenings, well-woman preventive visits,

breast and cervical cancer screenings, and HPV vaccination.[17,18]

In addition to full-benefit Medicaid expansion, limited-benefit Medicaid policies have extended eligibility

for family planning specific care since the 1990s. Medicaid section 1115 family planning demonstration

waivers are time-limited programs that extend coverage only for family planning services to additional

people low incomes who do not qualify for full-benefit Medicaid. Further, the ACA included a provision

for state plan amendments (SPAs) that enabled states to establish family planning expansion programs

by permanently amending their Medicaid state plan without the need for federal renewal.[19] Combined,

changes in these Medicaid policies led to substantial shifts in eligibility for family planning services

through Medicaid during 2008-2022.[20] Subsidies for directly purchasing private health insurance have

also made healthcare more affordable for women with low incomes during this period.[14] Public STI and

family planning clinics form additional key infrastructure for the family planning safety net in the U.S.,

but recent declines in other sources of federal and state funding to these clinics may have made revenue

from Medicaid relatively more important.[21,22]

Despite gains in health insurance coverage following the implementation of the ACA,[23] gaps in access

persist.[24] Increases in eligibility for Medicaid or subsidized health insurance do not always translate into

enrollment and utilization.[20] Persistent disparities and gaps in healthcare access likely mean continued

missed opportunities to prevent CS especially among certain groups. Racial, ethnic, and income

disparities in reported rates of syphilis have been documented, and rates are often increasing faster in

areas with higher levels of poverty.[25,26]

The objective of this analysis was to assess the relationship between the adoption of Medicaid expansion

policies and rates of CS in the United States. Numerous studies have explored the impact of Medicaid

expansion on a variety of health and economic outcomes.[27] However, the existence of limited-benefit

family planning waivers and SPAs might complicate the relevant timing of policy changes for sexual and

reproductive health outcomes affected by access to family planning services. For example, some states

that expanded full-benefit Medicaid in 2014 already had waivers or SPAs in place that extended access to

family planning services, meaning there was not have been a significant increase in eligibility for these

services when the state expanded Medicaid. Building on previous work that characterized the complex

policy landscape,[20] we use quasi-experimental designs to analyze Medicaid's impact on CS. Our work

highlights how adoption of Medicaid expansion policies might prevent CS and further costly downstream

health outcomes.

Methods

To assess how Medicaid expansion policies impact reported rates of CS, we leveraged policy variation

among states between 2008 and 2022 and implemented a novel estimator of difference-in-difference

(DiD) that accounts for variation in treatment timing. There were two primary policy changes, or

"treatments," of interest. Under the first, Medicaid expansion alone (ME), states were considered

treated if they had implemented Medicaid expansion. Under the second, Medicaid expansion plus

limited family planning policies (ME+LFP), states were considered treated if any of Medicaid expansion, a

family planning waiver, or a family planning SPA were in place at any point in a given year. The treatment

variable is binary where one means a state is treated in that year, and zero otherwise. Note that our

treatment variables measure policy adoption, not actual healthcare utilization or access. States were

considered treated based on policy implementation, regardless of subsequent enrollment levels or

service utilization. This shifts the timing of treatment for states that have a limited-benefit family

planning program in place at some point during the study period. In the analytic dataset, these

treatment variables were coded as binary indicators taking the value of one if a state was treated during

a given year and zero otherwise. States that experienced policy changes (e.g., ending a waiver program

or transitioning between policy types) were coded according to their treatment status in each specific

year. For the ME+LFP analysis, 26 states experienced treatment changes during the study period, with

most changes involving transitions to Medicaid expansion (n=16), followed by SPAs (n=7) and waivers

(n=3). One state experienced multiple treatment changes during the study period.

DiD estimators use two types of comparisons to calculate treatment effects. First, outcomes within a

state before treatment onset are compared to outcomes once treatment has begun. The change within a

treated state is then compared to the concurrent change in states that were not treated during that

same period (i.e., the controls). The controls included states during any years they were untreated.

Specifically, states served as controls if they either: 1) never implemented the policy during the study

period, or 2) had not yet implemented the policy in a given year.

There were two effect lengths highlighted in this analysis: the effect one year after the start of treatment

and the overall effect, which used three years of post-treatment data unless otherwise noted. Three

years was selected for the overall effect after treatment initiation for several reasons. First, expanding

the treatment length would result in fewer states meeting the inclusion criteria, reducing the sample size

as well as the precision of the estimates. For example, using a four-year window would exclude an

additional three states that expanded Medicaid after 2019. Second, a three-year window provides

sufficient time to observe policy effects while minimizing the influence of other concurrent policy

changes or external factors that could affect outcomes. We therefore dropped treated states with fewer

than three years of treated status in our main specification (n=2) to avoid changes in the effect due to

compositional changes from differences in the set of states used to determine the 1-year versus overall

effects. States that were always treated (e.g., had a waiver in place starting in 2008, n=21) were

systematically dropped from the ME+LFP analysis because they do not have pre-treatment data and are

not considered valid comparators. The preferred estimator for the DiD models was proposed by de

Chaisemartin and D'Haultfœuille (dCDH) and is well suited for this analysis because it accommodates

treatment switching and semi-continuous treatments, which were used in some sensitivity analyses.[28]

The primary model outcome is reported cases of CS per 100,000 live births. We hypothesized two basic

mechanisms through which family planning services might prevent cases of CS. First, STI testing and

treatment might reduce syphilis among women of reproductive age who are pregnant or who may later

become pregnant. Second, affordable access to contraception might reduce unintended pregnancies,

which may in turn reduce cases of CS. To test these hypotheses, we estimated models using two

additional outcomes: 1) the rate of primary and secondary (P&S) syphilis among women aged 15-24

years, and 2) total births per 1,000 women aged 15-19 years. Syphilis data were retrieved from the

National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention (NCHHSTP) AtlasPlus and live

birth outcomes from CDC Wonder.[29,30] Nearly half of reported STIs occur among adolescents and young

adults aged 15-24 years,[3] and this group is more likely to be enrolled in Medicaid.[31] Live birth data were

restricted to women aged 15-19 years because previous research found large effects of Medicaid family

planning policies within this group.[32]

We conducted a variety of sensitivity analyses. First, in place of a binary treatment indicator, the income

eligibility threshold for women without children (with the dCDH estimator) was used. Next, the

proportion of adult reproductive aged women (aged 18-44 years) who were eligible for family planning

services through Medicaid was estimated. The calculation of this variable is detailed in Williams et al.

(2024).[20] The effect of the size of the eligible population was estimated using an instrumental variables

estimator with year and state fixed effects, following Currie and Gruber (1996).[33] The instrumental

variable for a state's estimated eligible population was the national proportion of women that would be

eligible for Medicaid family planning if the state-level eligibility criteria were applied nationally. This

strategy accounts for the possibility that state decisions to implement policies were in part based on

state-specific demographic or economic trends, which would otherwise bias the estimated relationship.

A one-year lagged version of this estimator was also utilized. We did not estimate a model with a lagged

effect using the main specification because the dCDH estimator compares all other outcomes to the

period just before initiation of treatment. If there is any effect in the first year, then that becomes the

baseline in a lagged model and reduces estimated effects in later years. Next, additional models were

estimated that included covariates, included states that had been recently (i.e., less than three years)

treated, used four years of post-treatment data, or implemented the Callaway and Sant'Anna estimator.[34]

For sensitivity analyses of the mechanism models, we estimated models with the following additional

outcomes: P&S syphilis in women of reproductive age (15-44 years), overall live births (total births per

1,000 reproductive aged women), and the proportion of births to people with incomes below the

poverty level. Analyses were conducted using Stata 18 and R version 4.4.0.

The instrumental variable models included a variety of control variables: the proportion of adult

reproductive age women completing at least one year of higher education, mean income of adult

reproductive age women as a proportion of the federal poverty level, the proportion of adult

reproductive age women in households that received benefits from the Supplemental Nutrition

Assistance Program (SNAP), the proportion of the state population that is unemployed, the proportion of

the adult reproductive age female population that identifies as non-Hispanic Black, the proportion of the

adult reproductive age female population that identifies as non-Hispanic White, the proportion of the

adult reproductive age female population that identifies as Hispanic, the proportion of the state

population that migrated from out of state in the past year, the annual percent change in state

population, the proportion of the state population that is female, the proportion of the female

population that is between the ages of 15 and 24 years, and the proportion of the female population

that is between the ages of 25 and 44 years. Covariate data were derived from American Community

Survey data accessed via IPUMS.[35] Some covariate data were restricted to adult reproductive age women

(i.e., 18-44 years) because it mirrors eligibility for some government programs, including family planning

waivers in some states. The main dCDH specifications did not include covariates because 1) the

assumptions of parallel trends appeared to be satisfied without covariates (i.e., we observed parallel

trends in CS rates among treatment and non-treatment states prior to the onset of treatment), and 2)

not all covariates could be used in some treatment years because of the relatively small number of

control observations.[28]

Results

Twenty-seven states (including D.C.) expanded full-benefit Medicaid in 2014 (Supplemental Figure 1).

Three more states expanded in 2015, two in 2016, two in 2019, and three in 2020. Oklahoma and

Missouri expanded in 2021 but were not included in the main estimates because they did not have three

years of post-treatment data at the time this study was conducted. Thus, there were 37 states that

switched their treatment status under the ME treatment definition. For the ME+LFP treatment, 26 states

switched their treatment status during the study period (Supplemental Figure 2). The relevant treatment

change was Medicaid expansion in 16 states, SPAs in 7 states, and waivers in 3 states. Missouri and D.C.

had state funded programs that provided similar levels of family planning benefits prior to Medicaid

expansion and were thus designated as always-treated.[20] There were fewer total treatment changes

under the ME+LFP definition because many expansion states already had waivers in place prior to 2008

and therefore did not experience a change in treatment status. For example, Illinois had a family

planning waiver in place prior to 2008. When they expanded Medicaid in 2014, there was no change in

the ME+LFP treatment variable because they already had a Medicaid policy in place for family planning

services.

The mean rate of CS across states during 2008-2022 was 21.98 cases per 100,000 live births. There were

on average 6.38 cases of P&S syphilis per 100,000 women aged 15-44 years. Summary statistics for

additional outcome and control variables are presented in Table 1. There were no significant differences

in CS rates between treated and untreated states prior to Medicaid expansion (Figure 1). Using the main

model specifications, Medicaid expansion alone (ME) was associated with a reduction of 4.59 (95% CI:

1.62, 7.56) cases per 100,000 live births after one year and 6.37 (95% CI: 1.94, 10.79) cases per 100,000

live births overall (Table 2). Adopting Medicaid expansion, a family planning waiver, or a SPA (ME+LFP)

was associated with reductions of 3.37 (95% CI: 0.23, 6.51) cases per 100,000 and 5.06 (95% CI: -3.21,

13.33) cases per 100,000 after one year and overall, respectively.

Other treatment definitions resulted in similar CS rate reduction estimates, but only the lagged eligible

proportion estimate was statistically significant (3.73 cases per 100,000 overall effect, 95% CI: 0.58,

6.87). For secondary outcomes, there was some evidence of a reduction in P&S syphilis in women ages

15-24 (2.36 cases per 100,000 overall effect, 95% CI: 0.74, 3.97) and no evidence of an effect on live

births among women ages 15-19 (Table 3). The main results were generally robust when using

alternative models and specifications (Supplemental Table 1). The one-year effects were statistically

significant in all but one the CS outcome models, as were three of the five overall effects. The two

alternative live birth outcome models yielded no significant effect estimates.

Discussion

This analysis found robust evidence that Medicaid policies that increased eligibility for family planning

services were associated with declines in the rate of CS. Medicaid expansion alone was associated with a

significant reduction of over 6 cases per 100,000 live births compared to rates in non-expansion states,

equivalent to 29% of the mean rate of CS across states from 2008-2002. Medicaid expansion plus the

extension of family planning services through limited-benefit waivers or SPAs was associated with a

reduction of over 5 cases per 100,000 live births over three years of implementation, but the estimate

was not significantly different from zero. The difference in precision between the ME and ME+LFP results

does not necessarily mean that the family planning specific polices were themselves ineffective, rather

that the effect signal from the Medicaid expansion analysis, which didn't account for policies in place

prior to expansion, may have been stronger. There are a variety of reasons that may lead to less precise

effect estimates in our data. Limited-benefit waivers or SPAs, including those extending eligibility for

people who are pregnant or family planning, might be less publicized and well-known. Medicaid

expansion occurred in many states simultaneously and benefited from large scale outreach campagins.[36]

The heightened awareness might have led to more enrollment and service utilization. This is consistent

with previous work showing that even though higher pregnancy eligibility limits were in place prior to

implementation, Medicaid expansion improved timeliness and adequacy of prenatal care.[37] In addition,

in some states family planning program outreach was focused on existing clinic users.[19] This focus might

have resulted in a change in payer rather than increased utilization for those patients, although the influx

of Medicaid dollars might have expanded clinic capacity for future clients.[19] In addition, full-benefit

Medicaid expansion included access to additional preventive services beyond family planning, which

could have additional contributions to preventing CS.

The estimated effect on CS was statistically significant in the first year the policies were implemented

and grew slightly in magnitude over the first three years after policy adoption. Outreach and health

communication strategies in expansion states might have increased awareness of the upcoming policy

change and allowed people to quickly utilize the new benefits.[36] Given that diagnosing and treating

syphilis prior to pregnancy and early during pregnancy can be quickly accomplished when people

present to care,[1,2] it is reasonable that increasing access to clinical services that include syphilis

management would be able to prevent CS after just one year. The growing effect size over time is

unsurprising, as the prevention activities could impact pregnancy outcomes months to years after the

service was received. The instrumental variable estimates, using eligible population sizes, yielded

additional evidence to support a growing effect over time. In those sensitivity analyses, the estimated

effect was larger and more precise when the treatment variable was lagged one year.

We found that Medicaid expansion was associated with lowered P&S syphilis in women of reproductive

age, but we found no evidence of an association with live births. Lowering background rates of P&S

syphilis in women reduces the incidence of CS and its sequelae. Additionally, while access to affordable

contraception and preconception care could theoretically affect CS incidence in multiple ways, including

by reducing unintended pregnancy, our analysis found evidence only for reductions in P&S syphilis rates

as a potential mechanism. Previous evidence on the effect of limited family planning or full-benefit

Medicaid expansion on live birth outcomes has been mixed,[27] but some studies did find reductions in

births following the policy implementation.[32,38,39]

This analysis omits additional policy complexity that might be relevant for syphilis and CS outcomes.

States have phased out using waivers in favor of SPAs, but this analysis did not distinguish between those

two limited-benefit mechanisms and therefore might miss any potential benefits from switching to a

SPA. Medicaid eligibility extensions for people who are pregnant have been in place for decades.

However, pregnancy eligibility was fairly constant and did not vary substantially across states during the

time period of this analysis, so it should not impact the relevant timing of treatment in this analysis. In

addition, the ACA instituted marketplaces which may have facilitated access to insurance, required

private insurance plans cover certain family planning services, and extended dependent insurance

coverage until age 26. However, these changes were applied to all states simultaneously, so they should

not affect the DiD estimates. The Title X Family Planning Program, a domestic federal program dedicated

to ensuring access to high-quality, client-centered family planning care for millions of people with low

incomes or who are uninsured, may interact with Medicaid funding in complex ways but was omitted

from the current analysis.[22] Our treatment variables also capture policy adoption rather than actual

healthcare access or utilization. While policy implementation is necessary for expanding access to care,

other barriers such as awareness, enrollment processes, provider availability, and other factors can affect

whether eligible individuals ultimately receive services. Our estimates thus represent the intent-to-treat

effect of these policies rather than the effect of actually receiving services. While our 3-year post-

treatment window captured significant effects, longer-term impacts may differ. Additionally, the complex

nature of state policy changes, including transitions between different types of family planning coverage

and occasional policy reversals, required simplifying assumptions in our treatment coding that may not

fully capture all policy nuances. Finally, there is variation in state laws regarding the timing and frequency

of required screening for syphilis during pregnancy.[40]

This analysis provides new evidence on the potential impact of adopting Medicaid expansion policies on

CS prevention. Policymakers and public health professionals might consider these findings when

considering intervention alternatives for addressing the syphilis and CS epidemics. States could consider

the potential benefit of leveraging their Medicaid programs to reduce CS rates through expansion of

health insurance coverage, especially to people with low incomes who might not be able to otherwise

afford care, as well as the availability of low-cost family planning services. There are promising new

mechanisms for increasing eligibility for services through Medicaid that might be beneficial in CS

prevention among people who have limited access to social and medical services, including SPAs that

expand 12-month coverage during the postpartum period and section 1115 waivers that address health-

related social needs.[41] Further research might be beneficial to understand the complex relationships

between legislated policies and subsequent enrollment and utilization of services relevant for addressing

syphilis and CS. Mediating factors, such as health care workforce capacity, education efforts, and health,

also play important roles in the implementation and effectiveness of syphilis and CS prevention policies.

References

1.   McDonald R, O'Callaghan K, Torrone E, et al. Vital Signs: Missed Opportunities for Preventing Congenital Syphilis - United States, 2022. *MMWR Morb Mortal Wkly Rep*. Nov 17 2023;72(46):1269-1274. doi:10.15585/mmwr.mm7246e1

2.   Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. *MMWR Recomm Rep*. Jul 23 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1

3.   Division of STD Prevention. National Center for HIV/AIDS VH, STD, and TB Prevention. Centers for Disease Control and Prevention. *Sexually Transmitted Infections Surveillance, 2022*. 2024. https://www.cdc.gov/std/statistics/2022/default.htm

4.   Gomez GB, Kamb ML, Newman LM, Mark J, Broutet N, Hawkes SJ. Untreated maternal syphilis and adverse outcomes of pregnancy: a systematic review and meta-analysis. *Bull World Health Organ*. Mar 1 2013;91(3):217-26. doi:10.2471/blt.12.107623

5.   Umapathi KK, Thavamani A, Chotikanatis K. Incidence Trends, Risk Factors, Mortality and Healthcare Utilization in Congenital Syphilis-related Hospitalizations in the United States: A Nationwide Population Analysis. *Pediatr Infect Dis J*. Nov 2019;38(11):1126-1130. doi:10.1097/inf.0000000000002445

6.   Owusu-Edusei KJ, Introcaso CE, Chesson HW. Hospitalization Cost of Congenital Syphilis Diagnosis From Insurance Claims Data in the United States. *Sexually Transmitted Diseases*. 2013;40(3):226-229. doi:10.1097/OLQ.0b013e31827c5b9f

7.   Copen CE, Dittus PJ, Leichliter JS, Kumar S, Aral SO. Diverging trends in US male-female condom use by STI risk factors: a nationally representative study. *Sex Transm Infect*. Feb 2022;98(1):50-52. doi:10.1136/sextrans-2020-054642

8.   Lindberg LD, Firestein L, Beavin C. Trends in U.S. adolescent sexual behavior and contraceptive use, 2006-2019. *Contraception: X*. 2021/01/01/ 2021;3:100064. doi:https://doi.org/10.1016/j.conx.2021.100064

9.   Yan X, Jia Z, Zhang B. Evaluating the risk compensation of HIV/AIDS prevention measures. *The Lancet Infectious Diseases*. 2022;22(4):447-448. doi:10.1016/S1473-3099(22)00151-7

10.   Ramchandani MS, Golden MR. Confronting Rising STIs in the Era of PrEP and Treatment as Prevention. *Current HIV/AIDS Reports*. 2019/06/01 2019;16(3):244-256. doi:10.1007/s11904-019-00446-5

11.   Reno H, Fox B, Highfill C, et al. The Emerging Intersection Between Injection Drug Use and Early Syphilis in Nonurban Areas of Missouri, 2012-2018. *J Infect Dis*. Sep 2 2020;222(Suppl 5):S465-s470. doi:10.1093/infdis/jiaa056

12.   Plotzker RE, Burghardt NO, Murphy RD, et al. Congenital syphilis prevention in the context of methamphetamine use and homelessness. *Am J Addict*. May 2022;31(3):210-218. doi:10.1111/ajad.13265

13.   Rogers B, Tao J, Murphy M, Chan PA. The COVID-19 Pandemic and Sexually Transmitted Infections: Where Do We Go From Here? *Sex Transm Dis*. Jul 1 2021;48(7):e94-e96. doi:10.1097/olq.0000000000001445

14.   French MT, Homer J, Gumus G, Hickling L. Key Provisions of the Patient Protection and Affordable Care Act (ACA): A Systematic Review and Presentation of Early Research Findings. *Health Serv Res*. Oct 2016;51(5):1735-71. doi:10.1111/1475-6773.12511

15.   Tsai D. *Medicaid Family Planning Services and Supplies: Requirements and Best Practices*. 2024. https://www.medicaid.gov/federal-policy-guidance/downloads/cib08082024.pdf

16.   Ranji U, Bair Y, Salganicoff A. *Medicaid and Family Planning: Background and Implications of the*
ACA. 2016. https://www.kff.org/report-section/medicaid-and-family-planning-medicaid-family-planning-
policy/
17.   Ranji U, Gomez I, Salganicoff A, Rosenzweig C, Kellenberg R, Gifford K. Medicaid coverage of
family planning benefits: findings from a 2021 state survey. 2022;
18.   Health Resources & Services Administration. *Women's Preventive Services Guidelines*. 2024.
https://www.hrsa.gov/womens-guidelines
19.   Sonfield A, Gold RB. *Medicaid Family Planning Expansions: Lessons Learned and Implications for*
the Future. 2011. https://www.guttmacher.org/sites/default/files/pdfs/pubs/Medicaid-Expansions.pdf
20.   Williams AM, Saldarriaga EM, Cramer R. State-Level Trends in Access to Medicaid Family
Planning Services, 2008-2023. *Health Services Research*. 2024 Oct 22 2024;doi:10.1111/1475-
6773.14401
21.   Leichliter JS, Heyer K, Peterman TA, et al. US Public STD Clinical Services in an Era of Declining
Public Health Funding: 2013–14. *Sex Transm Dis*. 2017;44(8):505.
22.   Clochard A, Killewald P, Larson A, et al. *Family Planning Annual Report: 2022 National Summary*.
2023. https://opa.hhs.gov/research-evaluation/title-x-services-research/family-planning-annual-report-
fpar/fpar-archive
23.   Courtemanche C, Marton J, Ukert B, Yelowitz A, Zapata D. Early Impacts of the Affordable Care
Act on Health Insurance Coverage in Medicaid Expansion and Non-Expansion States. *J Policy Anal*
Manage. winter 2017;36(1):178-210. doi:10.1002/pam.21961
24.   Garfield R, Damico A, Orgera K. *The coverage gap: uninsured poor adults in states that do not*
expand Medicaid. 2018. https://digirepo.nlm.nih.gov/master/borndig/101740265/Issue-The-Coverage-
Gap-Uninsured-Poor-Adults-in-States-that-Do-Not-Expand-Medicaid.pdf
25.   Smock L, Caten E, Hsu K, DeMaria A. Economic Disparities and Syphilis Incidence in
Massachusetts, 2001-2013. *Public Health Reports®*. 2017;132(3):309-315.
doi:10.1177/0033354916688269
26.   Martin EG, Ansari B, Rosenberg ES, et al. Variation in Patterns of Racial and Ethnic Disparities in
Primary and Secondary Syphilis Diagnosis Rates Among Heterosexually Active Women by Region and Age
Group in the United States. *Sexually Transmitted Diseases*. 2022;49(5):330-337.
doi:10.1097/olq.0000000000001607
27.   Guth M, Diep K. *What Does the Recent Literature Say About Medicaid Expansion?: Impacts on*
Sexual and Reproductive Health. 2023. https://www.kff.org/medicaid/issue-brief/what-does-the-recent-
literature-say-about-medicaid-expansion-impacts-on-sexual-and-reproductive-health/
28.   De Chaisemartin C, d'Haultfoeuille X. Difference-in-differences estimators of intertemporal
treatment effects. *Review of Economics and Statistics*. 2024:1-45.
doi:https://doi.org/10.1162/rest_a_01414
29.   Centers for Disease Control and Prevention. NCHHSTP AtlasPlus. Accessed April 19, 2024,
https://gis.cdc.gov/grasp/nchhstpatlas/main.html
30.   Centers for Disease Control and Prevention. CDC WONDER. Accessed April 19, 2024,
https://wonder.cdc.gov/
31.   Foundation KF. Medicaid Enrollees by Age. Accessed January 13, 2025.
https://www.kff.org/medicaid/state-indicator/medicaid-enrollees-by-
age/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7
D
32.   Kearney MS, Levine PB. Subsidized Contraception, Fertility, and Sexual Behavior. *Rev Econ Stat*.
Oct 1 2009;91(1):137. doi:10.1162/rest.91.1.137
33.   Currie J, Gruber J. Saving Babies: The Efficacy and Cost of Recent Changes in the Medicaid
Eligibility of Pregnant Women *J Polit Economy*. 1996;104(6):1263-1296.

34.   Callaway B, Sant'Anna PHC. Difference-in-Differences with multiple time periods. *Journal of*
Econometrics. 2021;225(2):200-230. doi:https://doi.org/10.1016/j.jeconom.2020.12.001

35.   Ruggles S, Flood S, Sobek M, et al. Data from: IPUMS USA: Version 15.0. 2024. *Minneapolis, MN*.
doi:https://doi.org/10.18128/D010.V15.0

36.   Artiga S, Rudowitz R, Tolbert J. *Outreach and Enrollment Strategies for Reaching the Medicaid*
Eligible but Uninsured Population. 2016. Accessed July 25, 2024. https://www.kff.org/medicaid/issue-
brief/outreach-and-enrollment-strategies-for-reaching-the-medicaid-eligible-but-uninsured-population/

37.   Wherry LR. State Medicaid Expansions for Parents Led to Increased Coverage and Prenatal Care
Utilization among Pregnant Mothers. *Health Serv Res*. Oct 2018;53(5):3569-3591. doi:10.1111/1475-
6773.12820

38.   Eliason EL, Daw JR, Allen HL. Association of Affordable Care Act Medicaid Expansions with Births
Among Low-Income Women of Reproductive Age. *J Womens Health (Larchmt)*. Jul 2022;31(7):949-956.
doi:10.1089/jwh.2021.0451

39.   Lindrooth RC, McCullough JS. The effect of Medicaid family planning expansions on unplanned
births. *Womens Health Issues*. Mar-Apr 2007;17(2):66-74. doi:10.1016/j.whi.2007.02.012

40.   Division of STD Prevention. National Center for HIV/AIDS VH, STD, and TB Prevention. Centers for
Disease Control and Prevention. State Statutory and Regulatory Language Regarding Prenatal Syphilis
Screenings in the United States. Accessed July 23, 2024, https://www.cdc.gov/std/treatment/syphilis-
screenings.htm

41.   Hinton E, Diana A. *Section 1115 Medicaid Waiver Watch: A Closer Look at Recent Approvals to*
Address Health-Related Social Needs (HRSN). 2024. https://www.kff.org/medicaid/issue-brief/section-
1115-medicaid-waiver-watch-a-closer-look-at-recent-approvals-to-address-health-related-social-needs-
hrsn/

Table 1: Mean and Standard Deviation of Outcome Variables and Covariates

Variable	Mean	Standard Deviation
Outcomes		
CS rate	21.98	41.68
Primary and secondary syphilis rate (ages 15-44)	6.38	11.81
Primary and secondary syphilis rate (ages 15-24)	6.35	10.55
Total births per 1,000 women (ages 15-44)	62.01	7.35
Total births per 1,000 women (ages 15-19)	24.39	11.57
Proportion of births to women below the FPL	7.56%	1.98%
Alternative Treatment Variables		
Income eligibility threshold as percentage of FPL (for women without children)	138.92	95.84
Eligible Proportion	37.21%	18.02%
Covariates		
Proportion receiving SNAP benefits*	16.85%	5.1%
Proportion completing at least 1 year of higher education*	62.67%	5.4%
Income as a proportion of the FPL*	2.90	29.65
Proportion migrating from out of state in past year	3.54%	1.34%
State unemployment rate	4.97%	1.78%
Proportion of population that is female	50.60%	0.85%
Population growth	0.67%	0.85%
Proportion identifying as Black, Non-Hispanic*	12.84%	11.17%
Proportion identifying as White, Non-Hispanic*	67.64%	16.16%
Proportion identifying as Hispanic*	12.91%	11.14%
Proportion of the female population aged 15-44 years	13.13%	0.98%
Proportion of the female population aged 25-44 years	25.81%	2.06%

432 *Among women aged 19-44 years
433 CS: congenital syphilis
434 SNAP: supplemental nutrition assistance program
435 FPL: Federal Poverty Level
436

Table 2: Estimated change in the number of congenital syphilis cases per 100,000 live births after implementation of Medicaid policies

Treatment	**Main analyses**			**Sensitivity analyses**		
	ME: Medicaid expansion alone	**ME + LFP**: Medicaid expansion plus limited family planning policies	**Threshold**: Income eligibility threshold for women without children	**Eligibles**: Proportion eligible for family planning services through Medicaid	**Lagged Eligibles**: Previous year's proportion eligible for family planning services through Medicaid
One-Year Effect	**-4.59**	**-3.37**	-2.03		
[95% C.I.]	**[-7.56, -1.62]**	**[-6.51, -0.23]**	[-4.08, 0.03]		
Overall Effect	**-6.37**	-5.06	-3.31	-2.81	**-3.73**
[95% C.I.]	**[-10.79, -1.94]**	[-13.33, 3.21]	[-9.47, 2.86]	[-6.58, 0.96]	**[-6.87, -0.58]**

Bold indicates statistical significance at the 5% level.

ME: Medicaid expansion alone treatment definition (binary). Estimated using the dCDH method without covariates.

ME + LFP: Medicaid expansion plus family planning waiver/state plan amendment treatment definition (binary). Estimated using the dCDH method without covariates. See manuscript for an explanation of why the estimated effect of Medicaid expansion alone (ME) is greater than the estimated effect for Medicaid expansion plus limited family planning policies (ME + LFP).

Threshold: Continuous income eligibility threshold for women without children. Estimated using the dCDH method without covariates. Coefficients represents the change in CS rate associated with a 100-point increase in the income eligibility threshold.

Eligibles: The proportion of adult reproductive aged women eligible for family planning services through Medicaid. Estimated using instrumental variables method with covariates. Coefficients represent the change in CS rate associated with a 10-percentage point increase in the proportion of women eligible.

The overall effect used 3 years of post-treatment data for the ME, ME+LFP, and Threshold models, while all available years of data were used for the Eligibles models.

Table 3: Estimated change in P&S syphilis and live births after implementation of Medicaid policies

| | P&S Syphilis Rate (15-24) | | Live Birth Rate (15-19) | |
	ME: Medicaid expansion alone	ME + LFP: Medicaid expansion plus limited family planning policies	ME: Medicaid expansion alone	ME + LFP: Medicaid expansion plus limited family planning policies
One-Year Effect	**-1.66**	-0.76	0.07	-0.07
[95% C.I.]	**[-3.11, -0.21]**	[-2.37 0.84]	[-0.46, 0.60]	[-0.64, 0.49]
Overall Effect	**-2.36**	-1.54	0.14	-0.26
[95% C.I.]	**[-3.97, -0.74]**	[-4.93, 1.86]	[-0.62, 0.90]	[-1.16, 0.63]

Syphilis and live birth rates are among women. Bold indicates statistical significance at the 5% level. The
overall effect included 3 years of post-treatment data.

P&S: primary and secondary stages

ME: Medicaid expansion alone treatment definition. Estimated using the de Chaisemartin and
D'Haultfœuille (dCDH) method without covariates.

ME + LFP: Medicaid expansion plus family planning waiver/SPA treatment definition. Estimated using the
dCDH method without covariates.

Figure 1: Event Study - Relationship between Medicaid Expansion and the Rate of Congenital Syphilis

Supplemental Table 1: Alternative Models and Specifications for the Relationship between Medicaid Policies and CS, P&S Syphilis, or Live Births

Outcome	With Covariates CS Rate	With Covariates CS Rate	With MO and OK CS Rate	4-Year Effects CS Rate	Callaway and Sant'Anna CS Rate	Live Births Overall Live Birth Rate	Births Births to Women in Poverty	P&S Syphilis P&S Rate in Women Aged 15-44
1-Year Effect	**-5.24**	**-4.28**	-2.51	**-3.53**	**-4.59**	-0.11	-0.23	**-0.86**
[95% C.I.]	**[-8.03, -2.45]**	**[-8.24, -0.32]**	[-5.85, 0.83]	**[-6.51, -0.55]**	**[-8.77, -0.41]**	[-0.45, 0.21]	[-1.34, 0.91]	**[-1.70, -0.01]**
Overall Effect	**-6.00**	-5.27	-4.88	**-4.64**	**-6.37**	-0.20	-0.50	**-1.95**
[95% C.I.]	**[-10.17, -1.83]**	[-12.98, 2.43]	[-10.10, 0.32]	**[-8.55, -0.74]**	**[-11.48, -1.25]**	[-0.67, 0.26]	[-1.51, 0.51]	**[-3.42, -0.49]**
Treatment	ME	ME + FP	ME	ME	ME	ME	ME	ME
Covariates	YES	YES	NO	NO	NO	NO	NO	NO

ME: Medicaid expansion alone treatment definition. Estimated using the dCDH method.
ME + LFP: Medicaid expansion plus family planning waiver/SPA treatment definition. Estimated using the dCDH method.
CS: Congenital Syphilis
P&S syphilis: Primary and secondary syphilis
Missouri (MO) and Oklahoma (OK) expanded Medicaid in 2021 and do not have 3 years of post-treatment data. Excluding them avoids
compositional changes in the effect estimates. The overall effect included 3 years of post-treatment data for all specifications except in the 4-year
effect column.
483

Supplemental Figure 1: Timing of Medicaid Expansion by State

ME: Medicaid expansion alone treatment definition.

Supplemental Figure 2: Timing of Medicaid Family Planning Waivers, Medicaid Family Planning State Plan Amendments, and Full-Benefit
Medicaid Expansion, by State

ME + LFP: Medicaid expansion plus limited-benefit family planning waiver/state plan amendment (SPA) treatment definition. When a state has
overlapping policies, the color refers to the first policy implemented.

Supplemental Figure 3: Event Study - Relationship between Medicaid Expansion and Limited-Benefit
Family Planning Waivers/SPAs and the Rate of Congenital Syphilis

Supplemental Figure 4: Relationship between Medicaid Expansion and the Rate of Primary and
Secondary Syphilis among Women Aged 15-24